AMPA receptor activation potentiated by the AMPA modulator 1-BCP is toxic to cultured rat hippocampal neurons

Neuroscience Letters

Volumn 249, Issue 2-3, 1998, Pages 119-122

  Yamada, Kelvin A ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST LOUIS CHILDREN S HOSPITAL   (United States)

Author keywords

Ampakine; Benzothiadiazine; Benzoylpiperidine; Benzoylpyrrolidine; Cyclothiazide; IDRA21; Nootropic; Thiazide

Indexed keywords

AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; PIPERIDINE DERIVATIVE;

ANIMAL CELL; ARTICLE; BRAIN TOXICITY; HIPPOCAMPUS; LEARNING; MEMORY; NERVE CELL DEGENERATION; NONHUMAN; PRIORITY JOURNAL; RAT; SYNAPTIC TRANSMISSION;

ANIMALS; BENZOTHIADIAZINES; CELL SURVIVAL; CELLS, CULTURED; DIOXOLES; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; HIPPOCAMPUS; NEURONS; NEUROTOXINS; PIPERIDINES; QUINOXALINES; RATS; RECEPTORS, AMPA;

EID: 0032546897     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(98)00405-4     Document Type: Article

References (21)

1. Arai A., Guidotti A., Costa E., Lynch G. Effect of the AMPA receptor modulator IDRA 21 on LTP in hippocampal slices. NeuroReport. 7:1996;2211-2215.
2. Arai A., Kessler M., Xiao P., Ambros-Ingerson J., Rogers G., Lynch G. A centrally active drug that modulates AMPA receptor gated currents. Brain Res. 638:1994;343-346.
3. Buchan A.M., Li H., Cho S., Pulsinelli W.A. Blockade of the AMPA receptor prevents CA1 hippocampal injury following severe but transient forebrain ischemia in adult rats. Neurosci. Lett. 132:1991;255-258.
4. David J.C., Yamada K.A., Bagwe M.R., Goldberg M.P. AMPA receptor activation is rapidly toxic to cortical astrocytes when desensitization is blocked. J. Neurosci. 16:1996;200-209.
5. Ingvar M., Ambros-Ingerson J., Davis M., Granger R., Kessler M., Rogers G.A., Schehr R.S., Lynch G. Enhancement by an ampakine of memory encoding in humans. Exp. Neurol. 146:1997;553-559.
6. Lynch G., Kessler M., Rogers G., Ambros-Ingerson J., Granger R., Schehr R.S. Psychological effects of a drug that facilitates brain AMPA receptors. Int. Clin. Psychopharmacol. 11:1996;13-19.
7. Lynch G., Granger R., Ambros-Ingerson J., Davis C.M., Kessler M., Schehr R. Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans. Exp. Neurol. 145:1997;89-92.
8. May P.C., Robison P.M. Cyclothiazide treatment unmasks AMPA excitotoxicity in rat primary hippocampal cultures. J. Neurochem. 60:1993;1171-1174.
9. May P.C., Robison P.M. GYKI 52466 protects against non-NMDA receptor-mediated excitotoxicity in primary rat hippocampal cultures. Neurosci. Lett. 152:1993;169-172.
10. Moudy A.M., Yamada K.A., Rothman S.M. Rapid desensitization determines the pharmacology of glutamate neurotoxicity. Neuropharmacology. 33:1994;953-962.
11. Nellgard B., Wieloch T. Postischemic blockade of AMPA but not NMDA receptors mitigates neuronal damage in the rat brain following transient severe cerebral ischemia. J. Cereb. Blood Flow Metab. 12:1992;2-11.
12. Partin K.M., Fleck M.W., Mayer M.L. AMPA receptor flip/flop mutants affecting deactivation, desensitization, and modulation by cyclothiazide, aniracetam, and thiocyanate. J. Neurosci. 16:1996;6634-6647.
13. Patneau D.K., Vyklicky L.J., Mayer M.L. Hippocampal neurons exhibit cyclothiazide-sensitive rapidly desensitizing responses to kainate. J. Neurosci. 13:1993;3496-3509.
14. Sheardown M.J., Nielsen E.O., Hansen A.J., Jacobsen P., Honore T. 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia. Science. 247:1990;571-574.
15. Staubli U., Rogers G., Lynch G. Facilitation of glutamate receptors enhances memory. Proc. Natl. Acad. Sci. USA. 91:1994;777-781.
16. Staubli U., Perez Y., Xu F.B., Rogers G., Ingvar M., Stone-Elander S., Lynch G. Centrally active modulators of glutamate receptors facilitate the induction of long-term potentiation in vivo. Proc. Natl. Acad. Sci. USA. 91:1994;11158-11162.
17. Uzunov D.P., Zivkovich I., Pirkle W.H., Costa E., Guidotti A. Enantiomeric resolution with a new chiral stationary phase of 7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide, a cognition-enhancing benzothiadiazine derivative. J. Pharm. Sci. 84:1995;937-942.
18. Yamada K.A., Tang C.-M. Benzothiadiazides inhibit rapid glutamate receptor desensitization and enhance glutamatergic synaptic currents. J. Neurosci. 13:1993;3904-3915.
19. Yamada K.A., Dubinsky J.M., Rothman S.M. Quantitative physiological characterization of a quinoxalinedione non-NMDA receptor antagonist. J. Neurosci. 9:1989;3230-3236.
20. Yamada K.A., Covey D.F., Hsu C.Y., Hu R., Hu Y., He Y.Y. The diazoxide derivative IDRA 21 enhances ischemic hippocampal neuron injury. Ann. Neurol. 43:1998;664-669.
21. Zivkovic I., Thompson D.M., Bertolino M., Uzunov D., DiBella M., Costa E., Guidotti A. 7-Chloro-3-methyl-3-4-dihydro-2H-1,2,4 benzothiadiazine S,S-dioxide (IDRA 21): a benzothiadiazine derivative that enhances cognition by attenuating DL-alpha-amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolepropanoic acid (AMPA) receptor desensitization. J. Pharmacol. Exp. Ther. 272:1995;300-309.